Frankfurt am Main - Nanostart AG has acquired an equity stake in MagForce Nanotechnologies, the world’s leading company in the area of nanotechnological cancer treatment. The Berlin-based company is in possession of a patented technology which, with the aid of magnetic nanoparticles, enables a precise destruction of tumors.

"We are optimistic that the nano cancer therapy of MagForce could become established globally as a routine procedure. The method is simple and safe to use, has already undergone a long pre-development period and the studies carried out on the application of this therapy have already revealed major successes", Marco Beckmann, CEO of Nanostart AG, claims.

MagForce Nanotechnologies offers a revolutionary approach to nanotechnology-based cancer treatment. MagForce Nanotechnologies has advanced to become the world’s leading company in nano cancer therapy on the strength of its advanced technological development, the positive clinical data, a sound patent portfolio and experienced management. The first clinical study at Berlin’s Charité Hospital on MFH® treatment of glioblastomas, a particularly aggressive form of brain tumor, was recently completed and proclaimed a huge success. Two other studies corroborate the application potential of the technology of MagForce Nanotechnologies. The next chapter will consist above all in the continuation of the clinical trials, with the goal of already gaining a license and launching the product on the market in 2006.

Nanostart Investments AG:
Nanostart AG is one of the leading investors in the nanotechnology area. The company's two activity areas focus on investments in dynamically growing nanotechnology companies and advisory services to companies from the finance industry on investments in the nanotechnology sector. As nanotechnology investment company and sub-advisor for the DAC Nanotech-Fonds (ISIN LU0172295247), the company offers a unique profile in the global finance scene.